In breast cancer, patients with high Ki67 expression (> 30%) had worse disease-free survival and overall survival after adjuvant tamoxifen therapy (Elzawahry et al. 2013), while they could benefit from chemotherapy (Criscitiello et al. 2014). This evidence concerns the gene MKI67 and breast cancer.